🚨 Arch Biopartners announced the appointment of Dr. Patrick Vink, M.D., M.B.A., as Chairman of the Board, effective January 15, 2026. Dr. Vink brings extensive experience in global pharmaceutical leadership and governance.

📖 Full release:
archbiopartners.com/investor-hub

#ArchBiopartners #ArchNews

🚨 Arch Biopartners announced that St. Michael’s Hospital @unityhealthto.bsky.social received ethics approval to join the Phase II CS-AKI trial evaluating LSALT peptide.

🏥 4th Canadian site, 9th globally.

🔗 Read more (and share): www.archbiopartners.com/arch-biopart...

#LSALTpeptide #AKI #CSAKI

🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI.

📖 Latest News at www.archbiopartners.com/investor-hub/

#AKI #CSAKI #KidneyCare #NephSky

🚨 Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD).

🔬 Full News Release: archbiopartners.com/investor-hub/press-releases/

#KidneyCare #CKD #NephSky #ArchBiopartners

📊 A 2022 study in Kidney International (doi.org/10.1016/j.kint.2022.02.033) showed consistent AKI incidence and outcomes across Canada, Denmark, and the UK using harmonized KDIGO definitions.

Supports the need for targeted kidney therapies.

🔬 archbiopartners.com/our-science

#AKI #CSAKI #NephSky

Arch Biopartners’ CS-AKI Phase II clinical trial is now active at Toronto General Hospital, ranked Canada's #1 and #3 globally.

First patient dosed in the trial at this leading cardiac research hospital.

🔗 dub.sh/first-patien...

#ArchBiopartners #CSAKI #AKI #LSALTpeptide #clinicaltrials #ArchNews

🚨 Arch Biopartners now has two lead drug candidates in active Phase II trials:

🔹 Cilastatin: in the PONTIAK trial for drug-toxin-related AKI, now open for recruitment
🔹 LSALT peptide: cardiac surgery-associated AKI

🔗 archbiopartners.com/investor-hub...

#AKI #Cilastatin #LSALTpeptide #ArchNews

📢 Arch Biopartners’ May 2025 Corporate Presentation –Covers the CS-AKI and PONTiAK Phase II trials targeting inflammation- and toxin-related AKI.
📽️ Download the presentation and subscribe for updates at the Arch Investor Hub: www.archbiopartners.com/investor-hub/
#ArchBiopartners #CSAKI #InvestorFAQ